Glucocorticoids exert multiple anti-inf lammatory activities, one of which is the inhibition of transcription dependent on the nuclear factor (NF)-B. It has been suggested that the effect of dexamethasone (DEX), a glucocorticoid analog, is attributed to an increased production of the inhibitory IB molecule, which in turn would bind and remove activated, DNA-bound NF-B complexes in the cell nucleus. 
Glucocorticoids are potent immunosuppressive agents that are indispensable in development, cell proliferation, and differentiation processes and are also believed to be implicated in the inhibition of lymphocyte migration (1) . Their effects are exerted by binding to the intracellular glucocorticoid receptor (GR), which belongs to the family of steroid hormone receptors containing several functional domains. The modular structure consists of a variable N-terminal domain in which a transactivation function is localized, a DNA-binding domain comprising transactivation and dimerization functions, and a C-terminal ligand-binding domain that is also involved in transactivation, and dimerization as well as in nuclear translocation and binding to hsp90 (2) . In the resting state, GR is associated with two hsp90 molecules and one p59 immunophilin molecule. After binding of glucocorticoid hormone, this complex dissociates and the hormone-loaded receptor refolds into a homodimer. This new complex translocates to the nucleus and affects gene transcription either positively or negatively (3) .
Glucocorticoids can down-regulate the expression of several genes, including cytokines such as interleukin (IL)-6 induced by various inflammatory stimuli such as lipopolysaccharide, IL-1, or tumor necrosis factor (TNF) (4) (5) (6) . Mutational analysis identified various GR regions responsible for this repression (7) (8) (9) (10) (11) . Transcriptional repression of some genes, such as the pro-opiomelanocortin (12) , osteocalcin (13) , prolactin (14) , and proliferin (15) genes, has been reported to be mediated by a negative glucocorticoid response element (14, 16) . In the case of other genes, such as IL-6 (17), IL-8 (5), glycoprotein ␣-subunit (18) , and collagenase (19) , these elements could not be identified in the promoter. Recent studies, however, emphasize the importance of interactions between domains of GR and other transcription factors, such as AP-1, nuclear factor (NF)-B, CREB, OTF-1, and STAT5, as a possible way to explain the suppression of proinflammatory genes by glucocorticoids (4, (20) (21) (22) (23) (24) .
The promoter of the IL-6 gene contains a variety of binding sites for known transcription factors (25, 26) , which may cooperate or synergize to give a full response of gene expression in different cell types and conditions of induction (27, 28) . The main transcription factor for response to inflammatory cytokines is, however, NF-B (29) (30) (31) . This factor is a heterodimer that typically consists of a p65 (Rel A) and a p50 subunit. In a latent form, NF-B is sequestered in the cytoplasm through the ankyrin repeats of inhibitory B IB proteins (32, 33) . Activation of NF-B may occur through a variety of extracellular signals, which induce phosphorylation and ubiquitinylation events on IB-␣, resulting in proteolytic degradation (34) (35) (36) . Subsequently, NF-B is released from the inhibitor molecule and enters the nucleus, where it activates gene transcription. One such gene is the gene coding for IB-␣ itself, which is resynthesized and will resequester the transcriptionally active NF-B complexes, thus functioning in an autoregulatory fashion (33, 37) .
Here we investigated the molecular mechanism of downregulation of IL-6 synthesis by glucocorticoids in fibroblasts and endothelial cells, which are major producers of IL-6. It appeared that IL-6 repression did not result from IB-␣ up-regulation, as previously proposed (38, 39) , but is directly caused by down-modulation, through the activated GR, of the transactivation potential of p65 NF-B. serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin. Transgenic endothelial murine heart cells, TC10, which express immortalizing polyomavirus large T-antigen, were generously provided by L. E. Chalifour (Department of Microbiology and Immunology, McGill University, Montreal). They were cultured in DMEM containing 10% fetal calf serum (FCS), 100 units/ml penicillin, and 0.1 mg/ml streptomycin. The cells were irreversibly differentiated to a mature endothelial character by addition of 10 Ϫ6 M retinoic acid to the culture medium for 3 days (41) .
Cytokines and Reagents. Recombinant murine TNF, produced in our laboratory, had a specific biological activity of 1. Plasmids. pGal4, pGal4-p65, pGal4-p65 , pGal4-p65 , and pGal4-VP16 were described previously (42, 43) . The full IL-6 promoter of p1168hu.IL6P-lucϩ corresponds to a 1,168 bp HindIII-XhoI fragment of the human IL-6 promoter (44), whereas p50hu.IL6P-luc only contains the corresponding TATA box region (45) . p(Gal) 2 -50hu.IL6P-lucϩ and p(IL6-B) 3 50hu.IL6P-lucϩ are synthetic promoter constructs containing two palindromic GAL4 linkers or three NF-B response elements, respectively, preceding a 50-bp TATA box-containing IL-6 promoter fragment coupled to luc cDNA (figure 8 in ref. 45 ). pPGK␤geobpA, which contains a ␤-galactosidase (␤-gal)/ neomycin fusion gene, was a gift from P. Soriano (Fred Hutchinson Cancer Research Center, Seattle). pBR325 (46) was used as carrier DNA in transfections of eukaryotic cells.
The murine IL-6 cDNA fragment was made by a BamHI and EcoRI double-restriction digestion of pUC8 mIL-6 (47). The IB-␣ cDNA fragment was obtained by HindIII digestion of pRC/CMV-MAD-3. The cDNA fragment of the glyceraldehyde-3-phosphate dehydrogenase gene was isolated by digestion of pBluMGAPDHf (obtained from W. Kruijer, Dutch Institute for Developmental Biology, Utrecht, The Netherlands) with EcoRI. All cDNA fragments were used as probes in Northern blot analysis.
Site-Directed Mutagenesis. Site-directed mutagenesis of the IL-6 promoter was carried out following the gapped heteroduplex method (48) , by using a transformer site-directed mutagenesis kit (CLONTECH). The mutator oligonucleotide 5Ј-CTCCAACAAAGATTCTAGAAATGTGG-3Ј, which contains a specific BglII restriction site (altered nucleotides are underlined), was used to construct p1168hu.IL6P-lucϩ NFBmut. Mutant clones were screened for the presence of a newly created BglII restriction site and confirmed by sequence analysis. This mutation was already described to abolish NF-B binding with the purified recombinant protein (27) and was also tested for the biological effect on gene induction in corresponding, stably transfected clones (unpublished results).
Biological IL-6 Assay. Secreted IL-6 was quantitated according to its growth-stimulatory effect on 7TD1 cells. Cell proliferation was assessed by colorimetric determination of hexosaminidase levels (49, 50).
Electrophoretic Mobility-Shift Assay (EMSA). L929sA or TC10 cells were seeded in medium-sized Petri dishes at 10 6 cells per dish at day Ϫ1. After appropriate induction, the cells were washed with PBS, scraped off, and transferred to precooled Eppendorf tubes. EMSA were performed essentially as described (51) . DNA-binding activity was tested with an oligonucleotide containing the NF-B or Gal4-binding site. Equal amounts of protein were incubated with 2 g of poly(dI-dC) (Pharmacia), 20 g BSA, 0.1% (vol/vol) Nonidet P-40, 2 mM Hepes/KOH (pH 7.9), 2% (vol/vol) glycerol, 10 mM KCl, and 0.05 mM EDTA in combination with 4 l of 5ϫ binding buffer [20% (wt/vol) Ficoll 400/100 mM Hepes/KOH, pH 7.9/1 mM DTT/300 mM KCl] in a total volume of 20 l. After 10-min incubation, 10,000 cpm of [ 32 P]-labeled oligonucleotide was added and incubated on ice for 10 min. The free and protein-bound oligonucleotides were separated by electrophoresis on a native 4% polyacrylamide gel. Gel and running buffers contained 25 mM Tris, 25 mM boric acid, and 0.5 mM EDTA. After electrophoresis, the gel was dried and exposed to a PhosphorImager screen (Molecular Dynamics).
Labeling of the oligonucleotides was performed with [␥-32 P]-ATP by using T4 polynucleotide kinase or with [␣-
32 P]-dCTP by using Klenow enzyme (Boehringer Mannheim). The NF-B oligonucleotide comprises the sequences 5Ј-AGCTA-TGTGGGATTTTCCCATGAGC-3Ј (underlined: single B motif derived from the IL-6 promoter) and 3Ј-TACACCCTA-AAAGGGTACTCGTCGA-5Ј. The GAL4 oligonucleotide consists of the sequences 5Ј-GGCGGGTCGGAGTACTGT-CCTCCGACTGC-3Ј (underlined: single Gal4-binding site) and 3Ј-GCCCAGCCTCATGACAGGAGGCTGACGGAC-5Ј.
Western Blot Analysis. Cells were pretreated with 10 Ϫ6 M DEX, followed by incubation with 2,000 units/ml TNF. Cells were harvested and lysed in TOTEX buffer [20 mM Hepes/ KOH, pH 7.9/0.35 M NaCl/20% (vol/vol) glycerol/1% (vol/vol) Nonidet P-40/1 mM MgCl 2 /0.5 mM EDTA/0.1 mM EGTA/2 mM Pefabloc/5 mM DTT]. After centrifugation and addition of Laemmli buffer, the samples were loaded onto a reducing SDS/12% polyacrylamide gel and subjected to electrophoresis. Equal amounts of protein, determined according to Bradford (52) , were transferred to a polyvinylidene difluoride membrane (Bio-Rad). The membrane was washed twice in TBS/ 0.1% Tween, followed by incubation for at least 1 hr in the same compound supplemented with 5% nonfat, dry milk powder. The membrane was incubated in a small volume of TBS/0.1% Tween containing a 1:500 dilution of anti-IB-␣ antibody (Santa Cruz Biotechnology). After 4-hr incubation at room temperature, the membrane was washed 8 times in TBS/0.1% Tween and incubated for 1 hr in TBS/0.1% Tween, containing a 1:3,000 dilution of secondary anti-rabbit antibody coupled to horseradish peroxidase (Amersham). After extensive washing, the bound antibodies were detected by using enhanced chemiluminescence (Amersham).
Northern Blot Analysis. After appropriate inductions, RNA isolations were obtained by using TRIzol (Life Technologies, Paisley, U.K.). Briefly, 5 ϫ 10 6 TC10 cells were grown to subconfluency in 143-cm 2 Petri dishes and cells were induced with different combinations of DEX (10 Ϫ6 M), TNF (2,000 units/ml), and/or CHX (25 ng/ml). DEX and CHX were administered to the cells 1 hr before TNF induction, which lasted another 6 hr. Total RNA was isolated with TRIzol; denaturation was achieved with a combination of DMSO and deionized glyoxal (Sigma-Aldrich). A total of 20 g RNA was separated on a 1% agarose gel in 20 mM phosphate buffer (pH 7). RNA was transferred to Hybond-N ϩ membranes (Amersham) by standard capillary blotting and cross-linked by UV irradiation. Hybridization was done by sequentially probing with murine IL-6, human IB-␣, and murine glyceraldehyde-3-phosphate dehydrogenase cDNA fragments. The membrane was stripped (0.5% SDS for 5 min at 100°C) before each new Transfections. TC10 endothelial cells were seeded at 10 5 cells per 24-well on day Ϫ1. The cells were transiently transfected with lipofectamine (Life Technologies), the total amount being 600 ng of DNA per well. Lipofectamine was dissolved at a concentration of 12% in DMEM without serum. The amount of reporter plasmid p(Gal) 2 -50hu.IL6P-lucϩ was kept constant at 275 ng. pPGK␤geobpA allows to correct for transfection efficiencies and was also used at 275 ng. Fifty nanograms of pGal4, or 10, 25, or 50 ng of pGal4-p65 was used in various transfection assays. The total amount of DNA was adjusted to 600 ng with pBR325. One day later, the medium was replaced with fresh medium with or without DEX (10 Ϫ6
L929sA cells were transiently transfected with DEAEdextran (Pharmacia) essentially as described (53) . For stable transfection by calcium phosphate coprecipitation (54), 2 ϫ 10 6 actively growing L929sA cells were seeded per 75-cm 2 flask 24 hr before transfection. pGal4, pGal4-p65, or pGal4-VP16 were transfected together with pPGK␤geobpA. Cells were split on the first day and selection started with 500 g/ml G418 (Life Technologies) for at least 2 weeks.
RESULTS

Induction of IL-6 Transcription by TNF Is Repressed by DEX.
The inhibition by DEX of TNF-induced IL-6 gene expression in TC10 cells is shown in Fig. 1A . To ascertain whether this down-modulatory effect of DEX was also evident at the IL-6 mRNA level and whether it was still present in the absence of novel protein synthesis, Northern blot analysis was performed. In the endothelial cell system, the up-regulation of IL-6 mRNA levels was indeed suppressed by DEX (Fig. 1B) . The enhanced levels of IL-6 mRNA by treatment with CHX, an inhibitor of protein synthesis, were further up-regulated by TNF; the high induction level, obtained by a combination of CHX ϩ TNF, could still be suppressed by DEX (Fig. 1B) . This indicates that the repressive activity of DEX does not require new protein synthesis.
DEX Does Not Affect TNF-Activated IB-␣ mRNA. The Northern blots used for testing the effect of DEX on TNFinduced IL-6 mRNA synthesis were reprobed with IB-␣ cDNA (Fig. 1C) . The level of IB-␣ mRNA was increased by TNF or CHX. However, the level of induced IB-␣ mRNA was not enhanced further by the use of glucocorticoids.
DEX Treatment Does Not Interfere with the Formation of Active NF-B and Has No Effect on TNF-Activated IB-␣ Protein Levels.
The potential influence of DEX on TNFactivated NF-B in TC10 cells was tested by band-shift analysis. As evident from Fig. 2A , DEX had no effect on the DNA-binding activity of NF-B at any time point. Also, the levels of recombination binding protein-J (45) were not altered. Similar results were obtained in HeLa cells (data not shown) and L929sA cells (55) . IB-␣ protein levels tested at the same time points revealed that a combined treatment of TNF with DEX gave the same results as TNF alone (Fig. 2B) . Twenty minutes after TNF administration, IB-␣ was almost completely degraded, whereas it fully reappeared after 2 hr. At later time points, when repression was clearly visible at the level of IL-6 mRNA expression, the amount of IB-␣ protein was certainly not up-regulated by DEX treatment compared with induction with TNF alone.
DEX Repression Acts on B-Driven Promoters.
To study further the specificity of DEX repression, p1168hu.IL6P-lucϩ was stably transfected in L929sA cells. In the clones selected, luc gene expression by TNF treatment could reproducibly be induced and again repressed by treatment with DEX (Fig. 3) . For p(IL6-B) 3 -50hu.IL6P-lucϩ, TNF inducibility and repression by DEX showed a pattern similar to that obtained with p1168hu.IL6P-lucϩ. However, for the promoter constructs lacking a functional B site (i.e., p1168hu.IL6P-lucϩ NFBmut and p50hu.IL6P-lucϩ), no induction by TNF or repression by DEX could be observed. Although the levels of activated NF-B were not changed after addition of DEX (Fig.  2 A) , these experiments indicate that the repressive mechanism exerted by DEX was clearly directed against B-driven promoter constructs.
pGal4-p65-Mediated Expression of a Reporter Gene Can Be Repressed by DEX. A Gal4-based system was used to test whether the activated GR interfered with the transactivation potential of the p65 B subunit in the nucleus. L929sA cells were stably transfected with pGal4, pGal4-p65, pGal4-p65 , pGal4-p65 286-551 , or pGal4-VP16. These proteins are exclusively localized in the cell nucleus, as revealed by immunofluorescence studies (data not shown), and allow the monitoring of regulatory events, independently of IB effects. The corresponding transactivation capacity of the pGal4 plasmids and the downmodulation by DEX were measured after transient transfection of the respective cell lines with p(Gal) 2 -50hu.IL6P-lucϩ. As shown in Fig. 4A , the basal activation level mediated by pGal4-p65 2 and 6) , or induced for 6 hr with 2,000 units/ml TNF in the absence (lanes 3 and 7) or presence (lanes 4 and 8) of 10 Ϫ6 M DEX. The same series of treatments was performed in the presence of 25 ng/ml CHX (lanes 5-8). DEX and/or CHX were added, where appropriate, 1 hr before TNF. The respective induction levels were quantified and compared with the mRNA level in the noninduced state, which was arbitrarily set to 1. Rehybridization with a glyceraldehyde-3-phosphate dehydrogenase probe served as a control for equal loading. (C) DEX treatment does not influence the amount of TNF-activated IB-␣ mRNA. The filter shown in B was stripped and reprobed with human IB-␣.
was strongly suppressed by the addition of DEX, whereas no effect of DEX treatment was observed by using the control plasmid expressing Gal4 only. Moreover, activation by the strong, acidic VP16 in the cell line expressing the pGal4-VP16 fusion was also not repressed by DEX, showing that the repressive effect of glucocorticoids on p65-mediated transactivation is very specific. Furthermore, it is also clear from the experiments with the Gal4 deletion variants that repression by DEX acts as effectively with the C-terminal half only of the p65 molecule, i.e., where the domains for transcriptional activation are localized.
A similar pattern of gene repression by DEX in the Gal4 system was observed in TC10 cells transiently transfected with pGal4-p65 in combination with p(Gal) 2 -50hu.IL6P-lucϩ (Fig.  4B) . Also in this case, expression of the DNA-binding domain of Gal4 alone transactivated only marginally the Gal4-driven luc reporter gene.
The potential influence of DEX on the DNA-binding activity of the Gal4 fusion proteins was tested in a control experiment. After treatment with DEX for 12 or 24 hr, lysates were prepared from L929sA cells that stably expressed Gal4-p65. The DNA-binding activities of the fusion protein were tested in an EMSA assay by using a 32 P-labeled oligonucleotide containing a Gal4-binding site (Fig. 5) . The DNA-binding , pGal4-p65 286 -551 , or pGal4-VP16 were further transiently transfected with 700 ng p(Gal)2-50hu.IL6P-lucϩ, 700 ng of a plasmid containing ␤-gal, and carrier DNA, the total being 1.6 g DNA. After 72 hr, lysates were made and the concentration of luc was determined by using ␤-gal values as a basis for normalization. In appropriate assays, 10 Ϫ6 M DEX was added 24 hr before analysis. The normalized luc activity of the untreated samples was arbitrarily set to 100. Error bars show standard deviation of four independent experiments. (B) DEX represses p65 transactivation in TC10 cells. Cells were transiently transfected with pGal4 or pGal4-p65, together with a constant amount of p(Gal)2-50hu.IL6P-lucϩ, and treated with 10 Ϫ6 M DEX or untreated. After 24 hr, luc activity was determined by using ␤-gal values as a basis for normalization. Error bars show standard deviation of four independent transfections. activity of the Gal4 fusion protein was unchanged after treatment with DEX for up to 24 hr, indicating that the repressive effect of DEX was because of down-modulation of p65 transactivation, and not to a decrease in the expression levels of Gal4-p65 protein or in DNA-binding capacity.
DISCUSSION
Glucocorticoids are widely used in medicine for their antiinflammatory and immunosuppressive activities. It is generally accepted that their mechanism of action is based on repression of particular inflammatory (mostly cytokine) genes by the activated complex formed by the binding of the ligands to their corresponding intracellular receptors. However, the molecular mechanism of this gene repression is not yet fully understood. Recently, it has been reported that glucocorticoids enhance the expression of IB-␣ and a model has been proposed in which activation of NF-B, driving the inflammatory genes, could be counteracted by the reappearance of the inhibitory partner, thus slowing down and finally terminating the ongoing gene expression (38, 39) . This study shows that in endothelial cells the amount of TNF-activated NF-B was not affected by the addition of the synthetic glucocorticoid DEX, although there was clearly repression of IL-6 gene expression under these conditions. Also, in a previous study with murine fibroblast cells, it was shown that the levels of IL-6 mRNA, following induction with TNF, could be increased or decreased, irrespective of the amount of activated NF-B (55). Furthermore, we found that by treatment with DEX, the level of IB-␣ was unchanged at the mRNA and protein levels as compared with untreated or TNF-induced cells. This again demonstrates that removal of activated NF-B by an enhanced expression of IB-␣ cannot be the underlying mechanism for gene repression, at least not in endothelial cells. Such a mechanism is also not compatible with the finding that gene repression still occurred in the absence of protein synthesis.
Several reports suggest that down-modulation of B-driven genes results from a physical association between activated GR and the p65 B subunit, following overexpression of one or both of these proteins in transient transfection assays (4, 22, 56) . Our results indicate that gene activation by NF-B is repressed by glucocorticoids at the ''transcriptional'' level, both in murine fibroblasts and endothelial cells, and that this repression mechanism constitutes an exclusively nuclear mechanism. The activated, endogenous GR was able to specifically repress p65 B-dependent transactivation in a completely artificial Gal4 system, independently of the level of NF-B. Moreover, this effect was obtained by a normal physiological activation of endogenous GR. It may therefore well be that direct physical interaction between GR and p65 accounts for the observed down-modulation of gene expression. In this scenario, direct interaction between p65 and activated GR would mask the involved activation domain(s) of p65. Alternatively, direct interaction may also lead to modifications or conformational changes of p65, which would result in downmodulation of transcription. Furthermore, there is growing evidence that p65 exerts its transactivating function by interacting with components of the transcriptional machinery (57) , as well as with a number of coactivating factors (43, (58) (59) (60) . Thus, the model of induced gene activation has become more complex, and multiple protein/protein interactions might contribute to the repressive effects of activated GR on NF-B. Further studies will help to clarify whether these proteins are also involved in the repressive action of glucocorticoids on gene transcription.
